Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease symbols : Bivi save search
BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024
Published: 2024-03-01 (Crawled : 13:00) - globenewswire.com
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: 141.13%
H: 10.7%
C: -36.79%
ne3107 conference disease alzheimer’s international parkinson’s potential
BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease
Published: 2023-11-29 (Crawled : 13:00) - globenewswire.com
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: -67.54%
H: 33.95%
C: 20.99%
ne3107 disease alzheimer’s trial
BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023
Published: 2023-11-13 (Crawled : 13:30) - globenewswire.com
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: -4.57%
H: 1.5%
C: 0.0%
biv201 meeting liver disease association positive trial study
Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer’s Disease Patients
Published: 2023-10-25 (Crawled : 17:00) - globenewswire.com
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: -4.48%
H: 14.06%
C: -1.56%
ne3107 disease active alzheimer’s impact imaging
BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer’s Disease at CTAD
Published: 2023-10-19 (Crawled : 12:00) - globenewswire.com
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: -1.89%
H: 15.75%
C: 9.16%
ne3107 disease alzheimer’s
BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: 0.62%
H: 13.46%
C: 7.95%
ne3107 disease treatment alzheimer's trial
BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease
Published: 2023-09-11 (Crawled : 12:00) - globenewswire.com
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: 4.07%
H: 14.8%
C: 0.84%
ne3107 disease alzheimer’s trial study
BioVie Hosting Virtual KOL Event on NE3107 in Alzheimer’s Disease Today, September 7, 2023
Published: 2023-09-07 (Crawled : 12:00) - globenewswire.com
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: 0.0%
H: 5.96%
C: -1.8%
ne3107 disease alzheimer’s
BioVie to Host Virtual KOL Event on NE3107 in Alzheimer’s Disease on September 7, 2023
Published: 2023-08-31 (Crawled : 12:00) - globenewswire.com
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: 0.9%
H: 1.64%
C: -7.44%
ne3107 disease alzheimer’s
BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson’s Disease and Movement Disorders
Published: 2023-08-28 (Crawled : 12:00) - globenewswire.com
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: 0.3%
H: 3.13%
C: 1.18%
ne3107 disease international disorders parkinson’s
BioVie Presents Data Showing How NE3107 May Potentially Regulate DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease
Published: 2023-07-17 (Crawled : 11:00) - globenewswire.com
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: -0.59%
H: 3.3%
C: 0.8%
ne3107 disease dna biomarkers
BioVie to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease
Published: 2023-07-10 (Crawled : 12:20) - globenewswire.com
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: 0.23%
H: 6.97%
C: 5.17%
ne3107 disease dna biomarkers
BioVie Presents Data Highlighting Role of Insulin Resistance and Neuroinflammation in the Development of Mild to Moderate in Alzheimer’s Disease
Published: 2023-06-26 (Crawled : 12:00) - globenewswire.com
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: -4.29%
H: 3.94%
C: -14.16%
disease alzheimer’s insulin
BioVie To Present of NE3017 in Alzheimer’s Disease Data at 83rd Scientific Sessions of the American Diabetes Association
Published: 2023-06-21 (Crawled : 12:00) - globenewswire.com
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: 0.18%
H: 10.87%
C: 6.88%
ne3017 disease association alzheimer’s sessions diabetes
Parkinson's Disease Market to Exhibit Growth at a CAGR of 11.2% During the Study Period (2019-2032), Assesses DelveInsight
Published: 2023-05-30 (Crawled : 15:00) - prnewswire.com
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: -0.16%
H: 3.67%
C: -11.82%
disease parkinson's growth study market
BioVie Presents Rationale for Potentially Pivotal Trial of NE3107 in the Treatment of Parkinson’s Disease at 2023 International Association of Parkinsonism and Related Disorders World Congress
Published: 2023-05-16 (Crawled : 20:00) - globenewswire.com
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: 3.15%
H: 0.87%
C: -0.42%
ne3107 disease association international treatment parkinson’s trial
Parkinson's Disease Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 120 Key Companies Working in the Domain | DelveInsight
Published: 2023-04-19 (Crawled : 15:00) - prnewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -3.51%
H: 1.28%
C: 0.74%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.17%
H: 0.2%
C: -0.02%
VTGN | $4.83 1.05% 1.04% 190K
|
Health Technology
|
| O: 0.0%
H: 2.59%
C: -0.49%
DNLI | $16.11 0.75% 0.74% 1.1M
|
Health Technology
|
| O: -1.11%
H: 1.31%
C: 0.56%
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: -0.24%
H: 4.29%
C: 0.49%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -0.39%
H: 0.4%
C: -0.14%
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: 2.05%
H: 13.81%
C: 11.81%
AVXL | $3.68 0.0% 1.4M
|
Health Technology
|
| O: -0.74%
H: 2.73%
C: 1.61%
disease companies parkinson's pipeline space trial
BioVie Announces Data from Phase 2 Parkinson’s Disease Trial Accepted for Presentation at AD/PD 2023
Published: 2023-03-21 (Crawled : 12:20) - globenewswire.com
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: 1.95%
H: 9.13%
C: 8.28%
disease presentation parkinson’s trial phase 2
BioVie Announces Additional Findings from Phase 2 Parkinson’s Disease Trial: More patients treated with NE3107 experienced morning “on state” with levodopa withheld overnight compared to those treated with placebo
Published: 2023-03-06 (Crawled : 13:00) - globenewswire.com
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: -0.29%
H: 30.51%
C: 27.88%
ne3107 disease parkinson’s levodopa
BioVie Announces Completion of Patient Enrollment in Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease
Published: 2023-03-02 (Crawled : 14:00) - biospace.com/
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: -1.98%
H: 4.82%
C: -2.49%
ne3107 disease trial alzheimer’s
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.